Loading…
← CockpitCompetitor Analysis › 300294.SZ China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A300294.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

China Resources-affiliated plasma products maker producing albumin and immunoglobulin from donated human plasma.

≈ A Chinese CSL Behring/GrifolsMomentum neutral 55
Mkt cap
$959M
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$9.10M
20-day average traded
Fwd P/E
21.4×
forward earnings
ROIC−WACC
-8.9 pp
WACC 6.4%
Hurdle
n/a
no reverse DCF
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥13.02
1D-1.7%
1W-6.4%
1M-8.3%
3M-17.2%
6M-20.9%
YTD-42.4%
1Y-48.1%
ATR %2.6%
52w lowhigh49.2% off high

What China Resources Boya Bio-pharmaceutical does

China Resources-affiliated plasma products maker producing albumin and immunoglobulin from donated human plasma.

Raw plasma collected at licensed donation stations is the scarce input, so the number of stations and the plasma each collects limit output more than sales do; products then go mostly to hospitals through distributors. China Resources, a state-owned group, is the controlling shareholder.

In one line: A Chinese CSL Behring/Grifols.

Products and services

  • Human albumin
  • Immunoglobulin products
  • Other plasma-derived biologics

Customers

  • Hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • Biologics
  • Plasma-derived products

What could go right

  • Growing plasma collection stations
  • Hospital immunoglobulin demand

What could go wrong

  • Plasma supply constraints
  • Pricing regulation

Moat: narrow (regulatory licence, scale). Plasma-collection licences and blood-product manufacturing approvals are tightly state-regulated and slow to obtain.

Headquarters: Guangzhou, China · Employees: 1,947

Named competitors

China Resources Boya Bio-pharmaceutical at a glance

Size China Resources Boya Bio-pharmaceutical (300294.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $959M, the 2232nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥13.02 on 18 Nov 2026.

Performance Over six months the shares fell 20.9%, against -12.1% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue fell 27.1% over the last twelve months (peer median +9.8%); the operating margin is -18.7% (peer median 12.6%).

Valuation It trades at 21.4× forward earnings against a peer median of 23.7× (6th cheapest of 13).

Capital Return on invested capital runs 8.9 points below its cost of capital (6.4% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 87300294.SZ 81
Six months, rebased to 100: China Resources Boya Bio-pharmaceutical against the median of its 20 peers (local-currency closes).

China Resources Boya Bio-pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.43BCN¥2.05BCN¥1.73BCN¥2.64BCN¥2.75B
Revenue growth—+19%-35%-4%—
Gross profitCN¥649MCN¥937MCN¥1.06BCN¥1.33BCN¥1.44B
EBITDAn/aCN¥434MCN¥539MCN¥642MCN¥619M
Net income-CN¥168MCN¥113MCN¥397MCN¥237MCN¥432M
Free cash flow-CN¥445M-CN¥419MCN¥193MCN¥653MCN¥533M
Capital expenditureCN¥472MCN¥535MCN¥198MCN¥87.5MCN¥138M
Total debtCN¥167MCN¥333MCN¥220MCN¥74.2MCN¥68.4M

Quarterly statements and history in the cockpit →

China Resources Boya Bio-pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%6887592005STAR6035384565002437600422PGHLSPTX600129688382AARTIPHARM6881770392001795688710300294.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. China Resources Boya Bio-pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%20×40×60×2005STAR6035384565PGHL6001290392003004011795688710605116300294.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Resources Boya Bio-pharmaceutical is the large dot.

China Resources Boya Bio-pharmaceutical competitors and peer comparison

Head to head with its named competitors (300294.SZ vs 002252.SZ vs CSL.AX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
China Resources Boya Bio-pharmaceutical 300294.SZ$959M-21%-27%-19%21.4×n/a
Shanghai RAAS Blood Products 002252.SZ$4.57B-15%-22%17%12.8×n/a
CSL CSL.AX$63.7B+102%-2%26%21.5×6.8%

How China Resources Boya Bio-pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Resources Boya Bio-pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300294.SZPeer medianRank in peer set
1-month return-8.3%-9.1%10th highest of 21
6-month return-20.9%-12.1%8th lowest of 21
Distance from 52-week high-49.2%-41.9%8th lowest of 21
Revenue growth (TTM)-27.1%+9.8%4th lowest of 19
Operating margin-18.7%12.6%4th lowest of 19
Forward P/E21.4×23.7×6th cheapest of 13
ROIC minus cost of capital-8.9 pp-0.6 pp4th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%n/a10.3%-13.7%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%n/an/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%50.2×-10.2%+18.1%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%22.9×9.1%+13.4%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%9.8×-3.7%+13.8%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%

Questions

Who are China Resources Boya Bio-pharmaceutical's main competitors?
Named competitors: Shanghai RAAS Blood Products (002252.SZ), CSL Behring (CSL.AX). The cockpit's measured peer set (industry) also includes BeBetter Med (688759.SS), SSY (2005.HK), Strides Pharma Science (STAR.NS), Ningbo Menovo Pharmaceutical (603538.SS), Nxera Pharma (4565.T), Harbin Gloria Pharmaceuticals (002437.SZ).
Is China Resources Boya Bio-pharmaceutical expensive compared with its peers?
On forward p/e it trades at 21.4× against a peer median of 23.7×, 6th cheapest of 13 in its peer set.
How has China Resources Boya Bio-pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -20.9% against -12.1% for the median peer; over one year -48.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.